Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyrophosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
| ▸ | INPP5B | P32019 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.32 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.32 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL15874600 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL15421398 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL1872635 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL5195977 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL564839 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL1701118 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL334145 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL565146 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL22749766 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 | |
| Pyrophosphoric Acid SCHEMBL7153369 | 1.00 | FDPS (0.83) | FDPSBLMTDP1CA4INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53029962-A | — | — | None | — | — | JP | disclosed |
| CN-119230796-A | Anionic and cationic co-doped ferric sodium pyrophosphate positive electrode material, preparation method thereof and sodium ion battery | 贵州为方能源新材料科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023033636-A1 | METHOD OF PRODUCING HUMUS FERTILIZERS | КАЙСАНОВА, Гулмира Бакдаулетовна | 2023-03-09 | — | — | WO | disclosed |
| US-10426849-B2 | Staining composition | D.O.R.C. DUTCH OPHTHALMIC RESEARCH CENTER (INTERNATIONAL) B.V. (NL) | 2019-10-01 | — | — | US | disclosed |
| EP-2552491-B1 | STAINING COMPOSITION FOR USE IN A METHOD OF EYE SURGERY | MEDICAL TECH TRANSFER HOLDING B V (NL) | 2018-03-07 | — | — | EP | disclosed |
| US-20170258939-A1 | Staining Composition | D.O.R.C. DUTCH OPHTHALMIC RESEARCH CENTER (INTERNATIONAL) B.V. (NL) | 2017-09-14 | — | — | US | disclosed |
| US-9579401-B2 | Staining composition | MEDICAL TECHNOLOGY TRANSFER HOLDING B.V. (NL) | 2017-02-28 | — | — | US | disclosed |
| US-8932558-B2 | Multi-subunit biological complexes for treatment of plaque-associated diseases | PLAXGEN INC (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130045167-A1 | Staining Composition | MEDICAL TECHNOLOGY TRANSFER HOLDING B.V. (NL) | 2013-02-21 | — | — | US | disclosed |
| EP-2552491-A1 | STAINING COMPOSITION | Medical Technology Transfer Holding B.V. (NL) | 2013-02-06 | — | — | EP | disclosed |
| US-6849709-B2 | Aerothricin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2005-02-01 | — | — | US | disclosed |
| CN-1404486-A | Purified Luteinizing Hormone | APPLIED RESEARCH SYSTEMS (NL) | 2003-03-19 | — | — | CN | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1254161-A2 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | Basilea Pharmaceutica AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001053322-A2 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
| US-4493833-A | BACTERICIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-15 | — | — | US | disclosed |
| US-4304770-A | Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| JP-S5329962-A | PRODUCTION OF NOVEL GUANOCINEE5**DIPHOSPHORIC ACID MONOSODIUM DIHYDRATE CRYSTAL | YAMASA SHOYU KK | 1978-03-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045167-A1 | Staining Composition | CD68, MKI67, MMP1 | FDPS 1896/4885BLM 3169/4885TDP1 2288/4885 |
| US-20170258939-A1 | Staining Composition | CD68, MKI67, MMP1 | FDPS 1896/4885BLM 3169/4885TDP1 2288/4885 |
| US-10426849-B2 | Staining composition | CD68, MKI67, MMP1 | FDPS 1896/4885BLM 3169/4885TDP1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.